 BEDFORD, Mass.--BUSINESS WIRE--- OCUL OCUTX--Ocular TherapeutixTM, Inc. Nasdaq: OCUL, a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter financial results on Monday, November 8, 2021, after the market close. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcas 